← Eichor
Condition: Nsclc Recurrent Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nsclc Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 · 8 location(s) · Orano Med Theranostics, SAS · NCT05283330PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NA · 1 location(s) · University of Washington · NCT04151940Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
Phase 4 · 33 location(s) · AstraZeneca · NCT07279935SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NA · 6 location(s) · A.O.U. Città della Salute e della Scienza · NCT05689619Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060Anesthesia and Non-small Cell Lung Cancer Recurrence
Phase 4 · 1 location(s) · Samsung Medical Center · NCT06330038SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · University of Washington · NCT05570825Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Phase 2 · 1 location(s) · Diwakar Davar · NCT05669846Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastas
Phase 2 · 1 location(s) · Ayal A. Aizer, MD · NCT07130786A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924MRD Monitoring in Lung Cancer After Resection
Phase N/A · 1 location(s) · Guangdong Provincial People's Hospital · NCT04976296Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Phase 1/Phase 2 · 2 location(s) · University of Kansas Medical Center · NCT04467723First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07355205Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
Phase N/A · 2 location(s) · Shanghai Chest Hospital · NCT05701787Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Phase 1/Phase 2 · 1 location(s) · Precision Biotech Taiwan Corp. · NCT04616209Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Phase N/A · 1 location(s) · Samsung Medical Center · NCT03791034Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung C
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07057102RGL-270 + ICI in Advanced NSCLC
NA · 1 location(s) · Guangdong Association of Clinical Trials · NCT07652125Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin
Phase 2 · 1 location(s) · Ayal A. Aizer, MD · NCT07132190Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung
Phase 2 · 266 location(s) · SWOG Cancer Research Network · NCT06031688PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT05234307Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.